In hematopoietic cancer cells, the inhibitors of the NF-κB pathway induce VEGF secretion inhibition, thus reducing EC proangiogenic activities [85]. The gene discussed is VEGFA; the disease is hematopoietic and lymphoid cell neoplasm.